Arboretum Ventures

Arboretum Ventures has spent two decades demonstrating that you do not need to be in Boston, San Francisco, or New York to build a top-decile healthcare-only fund. From Ann Arbor, the firm has put roughly $1B to work across six funds in medical devices, diagnostics, life science tools, and tech-enabled care delivery, with a thesis that has barely shifted since founding: capital-efficient companies that improve outcomes while reducing total cost of care. The portfolio reflects that discipline. Francis Medical is developing water vapor ablation for prostate cancer. Pharaoh Neuroscience targets neurological indications. Boomerang Medical pursues neuromodulation for autoimmune disease. Allay Therapeutics is building long-acting pain management implants. Endogenex is working on duodenal mucosal regeneration for type 2 diabetes. The pattern is unmistakable: focused, single-indication device and therapeutic platforms with clear regulatory and reimbursement endpoints.

Arboretum’s investment thesis is healthcare-only and stage-flexible within early to mid-stage venture. The firm backs medical devices, diagnostics, life science tools, and tech-enabled care delivery, with a strong bias toward companies that can reach clinical and commercial inflection on modest capital. The implied target company has a defined clinical indication, a feasible FDA or CE pathway, a reimbursement strategy that does not require new code creation, and a management team capable of operational discipline. Because the firm is not splitting attention across software, fintech, or consumer, founders pitching Arboretum should expect a level of clinical and commercial diligence that generalist firms cannot match. The bias toward capital efficiency means platform plays requiring multiple sequential clinical programs are typically out of scope unless the first program can stand alone economically.

The disclosed portfolio illustrates how the thesis maps to actual deals. Francis Medical sits in urology, an underserved area with strong demographic tailwinds. Pharaoh Neuroscience and Boomerang Medical occupy adjacent neurological territory, the former in indication discovery, the latter in vagal and peripheral nerve modulation for inflammatory disease. Allay Therapeutics tackles the post-surgical pain market with a long-acting drug-eluting implant, sitting at the device-pharma boundary. Endogenex represents the firm’s appetite for metabolic disease beyond GLP-1 mechanisms. Sub-vertical concentration tilts toward devices, with selective diagnostics and tools exposure. Tech-enabled care delivery appears as a smaller slice. The takeaway: Arboretum’s actual deal flow is more device-heavy than the stated sub-vertical list might suggest, and software-only founders should calibrate accordingly.

Check size is listed at $5M to $25M, with Fund VI closing at $268M in 2023, putting the firm in a position to lead Series A and B rounds and reserve meaningfully for follow-on. Arboretum is a frequent lead, particularly for Series A in medtech, and partners with device specialists, regional funds, and strategics for syndication. The firm tends to take board seats and stay involved through commercial scale-up. In a market where many generalist firms have retreated from medtech, Arboretum’s continuity is a differentiator: founders get an investor who has seen the cycle from preclinical through commercialization across multiple product categories.

The partnership is unusually deep for a fund of this size. Jan Garfinkle, who founded the firm, is among the most respected medtech investors in the country and has served on the National Venture Capital Association board. Tom Shehab brings physician-investor experience. Dan Kidle adds operating credibility. Paul McCreadie covers partner-level investing as well as COO duties. Marcy Marshall handles finance as CFO. Nicole Vitullo serves as Venture Partner with deep biotech background. Jeff Terrell rounds out the partner-level team on the investment side. A typical first meeting is with one of Garfinkle, Shehab, Kidle, McCreadie, or Terrell, depending on therapeutic area and stage.

The warmest intro paths run through portfolio founder networks, fellow medtech specialist investors, and the academic device community at the University of Michigan and other Midwest institutions where Arboretum has long-standing ties. Garfinkle has spoken extensively at AdvaMed, MedCity News events, and on healthcare investing podcasts; her public commentary is unusually substantive on capital efficiency and clinical evidence. Founders can use her interviews to calibrate language and emphasis before reaching out. The firm is not driven by tech-press momentum and is unlikely to close a deal on hype.

Approach Arboretum once you have a defined clinical indication, a credible regulatory plan, and an early commercial hypothesis. Do not approach with a platform that has not yet picked its first indication, or with a software product lacking a clinical workflow anchor. Among portfolio founders, Arboretum is known as a patient, operationally engaged investor that holds positions through long device development cycles. The firm’s geographic and stylistic distance from coastal momentum is a feature, not a bug, for founders who want substantive board partnership over deal-velocity theatrics.